Literature DB >> 22675033

Long-term effectiveness of dobesilate in the treatment of papulopustular rosacea.

Pedro Cuevas1, Javier Angulo, Guillermo Giménez-Gallego.   

Abstract

This case report is a representative example from a study directed to assess the long-term clinical benefit of dobesilate in rosacea in five enrolled papulopustular rosacea patients with several years of disease, treated topically with 5% potassium dobesilate cream for 3 weeks. The patient suffered papulopustular rosacea for more than 10 years, during which she received topical metronidazole and azelaic acid, and systemic doxycycline therapies without satisfactory improvement. Dobesilate treatment promoted improvement of rosacea symptoms and signs. Two years after treatment the patient still shows a good facial cosmesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22675033      PMCID: PMC3207764          DOI: 10.1136/bcr.08.2011.4579

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Clinical practice. Rosacea.

Authors:  Frank C Powell
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  What is the pathogenesis of acne?

Authors:  C C Zouboulis; A Eady; M Philpott; L A Goldsmith; C Orfanos; W C Cunliffe; R Rosenfield
Journal:  Exp Dermatol       Date:  2005-02       Impact factor: 3.960

3.  Role of FGFR2-signaling in the pathogenesis of acne.

Authors:  Bodo C Melnik
Journal:  Dermatoendocrinol       Date:  2009-05

4.  Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate.

Authors:  Javier Angulo; Concepción Peiró; Tania Romacho; Argentina Fernández; Begoña Cuevas; Rocío González-Corrochano; Guillermo Giménez-Gallego; Iñigo Sáenz de Tejada; Carlos F Sánchez-Ferrer; Pedro Cuevas
Journal:  Eur J Pharmacol       Date:  2011-06-22       Impact factor: 4.432

5.  Expression of vascular endothelial growth factor and its receptors in rosacea.

Authors:  Justine R Smith; Virginia B Lanier; Rita M Braziel; Katherine M Falkenhagen; Clifton White; James T Rosenbaum
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

6.  Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.

Authors:  Israel S Fernández; Pedro Cuevas; Javier Angulo; Pilar López-Navajas; Angeles Canales-Mayordomo; Rocío González-Corrochano; Rosa M Lozano; Serafín Valverde; Jesús Jiménez-Barbero; Antonio Romero; Guillermo Giménez-Gallego
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

7.  Therapeutic response of rosacea to dobesilate.

Authors:  Pedro Cuevas; J M Arrazola
Journal:  Eur J Med Res       Date:  2005-10-18       Impact factor: 2.175

Review 8.  Interventions for rosacea.

Authors:  E J van Zuuren; M A Graber; S Hollis; M Chaudhry; A K Gupta; M Gover
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

Review 9.  Anti-acne agents attenuate FGFR2 signal transduction in acne.

Authors:  Bodo C Melnik; Gerd Schmitz; Christos C Zouboulis
Journal:  J Invest Dermatol       Date:  2009-02-19       Impact factor: 8.551

Review 10.  FGFR2 signaling and the pathogenesis of acne.

Authors:  Bodo Melnik; Gerd Schmitz
Journal:  J Dtsch Dermatol Ges       Date:  2008-09       Impact factor: 5.584

View more
  2 in total

1.  Durable recovery of the macular architecture and functionality of a diagnosed age-related macular degeneration 1 year after a single intravitreal injection of dobesilate.

Authors:  P Cuevas; L A Outeiriño; C Azanza; G Giménez-Gallego
Journal:  BMJ Case Rep       Date:  2013-11-13

2.  Improvement in the signs and symptoms of dry eye disease with dobesilate eye drops.

Authors:  Pedro Cuevas; Luis Antonio Outeiriño; Carlos Azanza; Javier Angulo; Guillermo Giménez-Gallego
Journal:  Mil Med Res       Date:  2015-12-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.